Astec Lifesciences Ltd's Q4FY25 Quarter Results
- 24 Apr 2025
Result Summary
- Astec Lifesciences Ltd reported a 62.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.3%.
- Its expenses for the quarter were up by 29.6% QoQ and 15.5% YoY.
- The net profit decreased 97.6% QoQ and decreased 80.7% YoY.
- The earnings per share (EPS) of Astec Lifesciences Ltd declined at 0.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 155.80 | 95.77 | 129.55 | 62.7% | 20.3% |
Total Expenses | 156.72 | 120.92 | 135.73 | 29.6% | 15.5% |
Profit Before Tax | -0.93 | -25.15 | -6.18 | -96.3% | -85.0% |
Tax | 0.04 | 15.22 | -1.21 | -99.7% | -103.3% |
Profit After Tax | -0.96 | -40.37 | -4.97 | -97.6% | -80.7% |
Earnings Per Share | -0.50 | -20.60 | -2.50 | -97.6% | -80.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Astec Lifesciences Ltd is a prominent player in the agrochemical sector, primarily engaged in the production and supply of active ingredients, intermediates, and formulations. The company is known for its extensive product portfolio which includes herbicides, fungicides, and insecticides. These products cater to the agricultural industry, serving as vital inputs for crop protection and yield enhancement. Astec Lifesciences has been focusing on expanding its manufacturing capabilities and strengthening its research and development to innovate new products and improve existing formulations. As of the latest available data, no major recent developments or acquisitions have been noted.
Revenue
Astec Lifesciences Ltd reported a significant increase in total income for Q4FY25 at ₹155.80 crores, compared to ₹95.77 crores in Q3FY25, marking a quarter-over-quarter growth of 62.7%. This indicates a substantial rise in revenue generation within the quarter. On a year-over-year basis, the total income increased by 20.3% from ₹129.55 crores in Q4FY24, reflecting a positive trend in revenue growth over the year. The company's ability to boost its total income by such margins highlights an increase in sales performance or improved operational efficiencies over the periods in question.
Profitability
The profitability metrics for Astec Lifesciences indicate significant fluctuations. The company recorded a loss in profit before tax (PBT) of ₹-0.93 crores for Q4FY25, which is an improvement compared to the loss of ₹-25.15 crores in Q3FY25. This represents a notable QoQ improvement of 96.3%. Compared to the same quarter last year, where the PBT was ₹-6.18 crores, the YoY improvement is 85.0%. Similarly, the profit after tax (PAT) for Q4FY25 was ₹-0.96 crores, a QoQ improvement of 97.6% from the ₹-40.37 crores in Q3FY25, and an 80.7% YoY improvement from ₹-4.97 crores in Q4FY24. These figures suggest a trend towards narrowing losses over both the quarterly and annual periods.
Operating Metrics
The operating metrics highlight certain key trends in Astec Lifesciences' financial performance. Total expenses for Q4FY25 stood at ₹156.72 crores, showing an increase of 29.6% from ₹120.92 crores in Q3FY25, and a 15.5% rise from ₹135.73 crores in Q4FY24. The earnings per share (EPS) also demonstrated improvement, recorded at ₹-0.50 in Q4FY25, compared to ₹-20.60 in Q3FY25, and ₹-2.50 in Q4FY24, indicating a 97.6% QoQ and 80.0% YoY improvement. These figures suggest that the company has managed its operating costs and expenses effectively, leading to better EPS outcomes over the periods in question. This could be indicative of operational efficiencies or changes in cost structures.
